Encompass Health Corporation (NYSE:EHC) settled a seven-year False Claims Act (“FCA”) investigation by the Department of Justice (“DOJ”), together with related qui tam or “whistleblower” lawsuits, for a settlement payment of $48 million. In the settlement, the Company expressly denies any wrongdoing. The Company will not be subject to a Corporate Integrity Agreement (“CIA”).
The stock Earnings per share (EPS) and the diluted EPS are the profitability measures used in the fundamental analysis of companies. The figure of EPS only takes into account a Encompass Health Corporation (NYSE:EHC) common shares, whereas the very important diluted EPS take into account all the convertible securities such as convertible bonds/convertible preferred stock, which are changed into equity or common stock. Dilutive effects occur when the number of shares increases, for example, through a new issue. If a company issues more shares to shareholders and other investors, this increases the number of shares outstanding and decreases the company’s earnings per share. Ultimately, this can decrease the stock price. Encompass Health Corporation (NYSE:EHC) Diluted EPS is 3.86, whereas the EPS Estimate for next year is 3.11. The Annual EPS Growth of past 5 years is 5.40% and Encompass Health Corporation (NYSE:EHC) yearly performance is -5.55% and net profit margin is 7.10%.
Key Performance indicators for Encompass Health Corporation (NYSE:EHC), in last 4 months the performance of EHC was 8.49% while its price to sale ratio is 1.43 and price to book ratio is 4.74. Company gross margin stands at 96.40% whereas its return on investment (ROI) is 13.40%.
On 28 June 2019, Encompass Health Corporation (NYSE:EHC), a Healthcare sector firm, traded 1.79 Million shares in last trading session and stock moved up 2.21% with closing price of $63.36 per share. with Encompass Health Corporation (NYSE:EHC) traded 1.79 Million shares. The EHC distance from 20 day simple moving average is 4.25% and distance from 50-Day simple moving average is 3.52%.The relative strength index for stock is 61.99 and Average true range of EHC is 1.35.
Analyst’s mean target price for EHC is $78.27 while analysts mean recommendation is 1.90. The Stock value has moved between $56.57 – 82.29 in last one year. EHC market capitalization is 6234.62 with beta of 0.80. Company has 1.60% insider ownership.
Encompass Health Corporation (NYSE:EHC) is under coverage by number of analysts. Stock has got OUTPERFORM rating from 10 of Thomson Reuters analysts, 2 given HOLD rating to the stock and 0 given UNDERPERFORM rating. Buy rating has been given by 4 analysts to the company stock.